{u'PublicationType': u'Journal', u'PublicationYear': 2004, u'Title': u'Role of natural killer cells in innate protection against lethal Ebola virus infection.', u'@id': u'200440776', u'Settings': {u'Setting': u'Preclinical'}, u'Organisations': {u'Organisation': [u'Nat.Cancer-Inst.Frederick', u'Univ.Washington-St.Louis']}, u'Profiles': {u'Profile': [u'Immunological', u'Drug Targets', u'Virucides']}, u'Teaser': u'I.p. or i.m. administration of non-replicating <b>Ebola</b> virus-like particles (VLP) containing the glycoprotein (GP) and matrix protein virus protein (VP40) induced protective immunity in mice challenged with <b>Ebola</b> virus. Innate protection against <b>Ebola</b> virus required NK cells. <b>Ebola</b> VLPs induced strong NK cytotoxic activity, as well as cytokine and chemokine secretion. NK cell-mediated protection against <b>Ebola</b> virus was perforin dependent, but did not depend on interferon-gamma secretion. Particles containing...', u'PublicationName': u'J.Exp.Med.', u'Location': u'Frederick, Md., Washington, D.C.; St. Louis, Mo., USA', u'Authors': {u'Author': [u'Warfield K L', u'Perkins J G', u'Swenson D L', u'Deal E M', u'Bosio C M', u'Aman M J', u'Yokoyama W M', u'Young H A', u'Bavari S']}, u'Keywords': {u'Keyword': u'INFECTION,VIRUS/OC IN-VIVO/FT MOUSE/FT I.P./FT I.M./FT EBOLA-VIRUS/FT VACCINES/FT VACCINE/FT IMMUNE-RESPONSE/FT MORTALITY/FT SURVIVAL/FT NAT.KILLER-CELL/FT INTERLEUKIN-2/FT INTERFERON-GAMMA/FT DRUG-TARGET/FT LAB.ANIMAL/FT INJECTION/FT VIRUS/FT IMMUNITY/FT LYMPHOCYTE/FT PH/FT'}, u'IssueDate': u'2004-11-23T00:00:00Z', u'MethodOfAction': {u'Method': [u'VACCINE', u'VACCINES']}, u'ThematicGroups': {u'ThematicGroup': [u'Pharmacology', u'Microbiology']}}{u'PublicationType': u'Review', u'PublicationYear': 2008, u'Title': u'A DNA vaccine for the prevention of Ebola virus infection.', u'@id': u'200821626', u'Settings': {u'Setting': u'Clinical'}, u'Organisations': {u'Organisation': u'Univ.Tulane'}, u'Profiles': {u'Profile': [u'Immunological', u'Reviews', u'Virucides', u'Clinical Trials', u'Adverse Reactions', u'Infection', u'Pharmacokinetics']}, u'Teaser': u"A DNA vaccine for the prevention of <b>Ebola</b> virus infection is reviewed with respect to: synthesis and SAR; preclinical development; toxicities; metabolism and pharmacokinetics; clinical development; and side effects and contraindications. Vaccines discussed are gamma-irradiated whole <b>Ebola</b> virus, inactivated <b>Ebola</b> virus, DNA vaccine, VRC-EBODNA012-00-VP, Vical's DNA vaccine, <b>Ebola</b> virus Zaire GP, <b>Ebola</b> virus Zaire GP and NP, <b>Ebola</b> virus DNA vaccine, rAd5-baed...", u'PublicationName': u'Curr.Opin.Mol.Ther.', u'Location': u'New Orleans, LA, USA', u'Authors': {u'Author': [u'Dery M', u'Bausch D G']}, u'Keywords': {u'Keyword': u'EBOLA-VACCINE/AE EBOLA-VACCINE/PH EBOLA-VACCINE/DM EDEMA/AE ERYTHEMA/AE PAIN/AE DERMATOLOGY/AE ASTHENIA/AE HEADACHE/AE NAUSEA/AE PYREXIA/AE VACCINES/FT VACCINE/FT VACCINATION/FT HUMAN/FT IN-VIVO/FT ANIMAL-MODEL/FT PHARMACOKINETICS/FT EBOLA-VIRUS/FT ANTIVIRAL/FT PHASE-I/FT CLIN.TRIAL/FT I.M./FT IN-VITRO/FT MAIN-TOPIC/FT RANDOM/FT PLACEBO/FT BLIND-TEST/FT DOUBLE/FT CD4+-CELL/FT LYMPHOCYTE/FT THYMOCYTE/FT INTRACELL./FT PER-C6-CELL/FT 293-CELL/FT REVIEW/FT VIRUS/FT INJECTION/FT TISSUE-CULTURE/FT AE/FT PH/FT DM/FT'}, u'IssueDate': u'2008-07-03T00:00:00Z', u'MethodOfAction': {u'Method': [u'ANTIVIRAL', u'VACCINE', u'VACCINES']}, u'ThematicGroups': {u'ThematicGroup': [u'Therapeutics', u'Pharmacology', u'Adverse Effects', u'Microbiology']}}{u'PublicationType': u'Review', u'PublicationYear': 2003, u'Title': u'Minireview. Ebola Virus Pathogenesis: implications for vaccines and therapies.', u'@id': u'200345431', u'Settings': {u'Setting': u'Clinical'}, u'Organisations': {u'Organisation': u'Nat.Inst.Health-Bethesda'}, u'Profiles': {u'Profile': [u'Immunological', u'Reviews', u'Infection', u'Gene Therapy']}, u'Teaser': u'The pathogenesis of the <b>Ebola</b> virus is reviewed with reference to implications for vaccines and therapies. <b>Ebola</b> virus disease progression, structure and classification of the <b>Ebola</b> virus, the immune response to <b>Ebola</b> virus infection and vaccine development are discussed. Live attenuated viruses and recombinant proteins have been used successfully in many experimental <b>Ebola</b> virus vaccines. However, gene-based vaccines are becoming an increasingly attractive option. DNA vaccines have been highly effective...', u'PublicationName': u'J.Virol.', u'Location': u'Bethesda, Md., USA', u'Authors': {u'Author': [u'Sullivan N', u'Yang Z Y', u'Nabel G J']}, u'Keywords': {u'Keyword': u'INFECTION,VIRUS/OC VACCINES/FT VACCINE/FT REVIEW/FT MAIN-TOPIC/FT PATHOGENESIS/FT EBOLA-VIRUS/FT GENE-THERAPY/FT PLASMID/FT DNA/FT IN-VIVO/FT CASES/FT LAB.ANIMAL/FT PROPHYLAXIS/FT IMMUNIZATION/FT VACCINATION/FT IMMUNE-RESPONSE/FT VIRUS/FT IMMUNITY/FT TR/FT PH/FT'}, u'IssueDate': u'2003-11-12T00:00:00Z', u'MethodOfAction': {u'Method': [u'GENE-THERAPY', u'VACCINE', u'VACCINES']}, u'ThematicGroups': {u'ThematicGroup': [u'Therapeutics', u'Microbiology']}}{u'PublicationType': u'Journal', u'PublicationYear': 2003, u'Title': u'Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.', u'@id': u'200333490', u'Settings': {u'Setting': u'Preclinical'}, u'Organisations': {u'Organisation': [u'Nat.Inst-Health-Bethesda', u'U.S.Army-Med.Res.Inst.Infec.Dis.']}, u'Profiles': {u'Profile': u'Immunological'}, u'Teaser': u'I.m. vaccination with adenoviral (ADV) vector encoding the <b>Ebola</b> glycoprotein (GP) or nucleoprotein (NP) protected monkeys against lethal challenge with <b>Ebola</b> virus infection. Protection was highly effective and was correlated with the generation of Eloba-specific CD8+ T-cell and Ab responses. Even a single ADV-GP/NP injection protected against viral challenge. Results suggest that this accelerated vaccine provides an intervention that may help to limit the epidemic spread of <b>Ebola</b>, and is applicable to other viruses.', u'PublicationName': u'Nature', u'Location': u'Bethesda; Fort Detrick, Md., USA', u'Authors': {u'Author': [u'Sullivan N J', u'Geisbert T W', u'Geisbert J B', u'Xu L', u'Yang Z Y', u'Roederer M', u'Koup R A', u'Jahrling P B', u'Nabel G J']}, u'Keywords': {u'Keyword': u'INFECTION,VIRUS/OC IN-VIVO/FT MONKEY/FT I.M./FT ADENOVIRUS/FT VIRAL-VECTOR/FT EBOLA-VIRUS/FT IMMUNIZATION/FT CD8+-CELL/FT CD4+-CELL/FT IGG/FT ANTIBODY-TITER/FT IMMUNE-RESPONSE/FT VACCINE/FT VACCINES/FT LAB.ANIMAL/FT INJECTION/FT VIRUS/FT VECTOR/FT GENE-TRANSFER/FT VIRUS/FT THYMOCYTE/FT LYMPHOCYTE/FT THYMOCYTE/FT LYMPHOCYTE/FT IMMUNOGLOBULIN/FT IMMUNITY/FT PH/FT'}, u'IssueDate': u'2003-08-19T00:00:00Z', u'MethodOfAction': {u'Method': [u'VACCINE', u'VACCINES']}, u'ThematicGroups': {u'ThematicGroup': u'Pharmacology'}}{u'PublicationType': u'Journal', u'PublicationYear': 2003, u'Title': u'Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.', u'@id': u'200402264', u'Settings': {u'Setting': u'Preclinical'}, u'Organisations': {u'Organisation': u'Corvas'}, u'Profiles': {u'Profile': [u'Hematological', u'Biol. Response Modifiers']}, u'Teaser': u'In a rhesus macaque model of <b>Ebola</b> hemorrhagic fever, s.c. recombinant nematode anticoagulant protein c2 (rNAPc2), a potent...factor-initiated blood coagulation, administered 10 min or 24 hr after lethal injection of <b>Ebola</b> virus prolonged survival time. RNAPc2 attenuated the coagulation response. Furthermore...in the treated than the untreated macaques. Post-exposure protection with rNAPc2 against <b>Ebola</b> virus in primates provides a new foundation for therapeutic regimens that target the disease...', u'PublicationName': u'Lancet', u'Location': u'Fort Detrick; Frederick, Md., Hurst, Tex.; San Diego, Cal., USA', u'Authors': {u'Author': [u'Geisbert T W', u'Hensley L E', u'Jahrling P B', u'Larsen T', u'Geisbert J', u'Paragaas J', u'Young H A', u'Fredeking T M', u'Rote W E', u'Vlasuk G P']}, u'Keywords': {u'Keyword': u'NEMATODE-ANTICOAGULANT-PROTEIN-C2/PH INFECTION,VIRUS/OC RHESUS/FT MONKEY/FT IN-VIVO/FT S.C./FT RECOMBINANT/FT ANTICOAGULANT/FT EBOLA-VIRUS/FT BLOOD-PLASMA/FT INTERLEUKIN-6/FT MONOCYTE-CHEMOATTRACTANT-PROTEIN-1/FT LAB.ANIMAL/FT INJECTION/FT VIRUS/FT ANTICOAGULANTS/FT PH/FT'}, u'IssueDate': u'2004-01-15T00:00:00Z', u'MethodOfAction': {u'Method': [u'ANGIOGENESIS-INHIBITORS', u'ANTICOAGULANT', u'ANTICOAGULANTS', u'CYTOSTATICS']}, u'ThematicGroups': {u'ThematicGroup': u'Pharmacology'}}{u'PublicationType': u'Review', u'PublicationYear': 2011, u'Title': u'Recombinant Vesicular Stomatitis Virus-Based Vaccines Against Ebola and Marburg Virus Infections.', u'@id': u'201213871', u'Settings': {u'Setting': u'Clinical'}, u'Organisations': {u'Organisation': [u'Univ.Texas-Syst.', u'Nat.Inst.Health-Hamilton', u'Public-Health-Agency-Canada', u'Univ.Manitoba']}, u'Profiles': {u'Profile': [u'Immunological', u'Reviews', u'Adverse Reactions', u'Infection', u'Toxicology']}, u'Teaser': u'Recombinant vesicular stomatitis virus-based vaccines against <b>Ebola</b> and Marburg virus infections are reviewed with reference to: <b>Ebola</b> and Marburg viruses; recombinant vesicular stomatitis virus as a vaccine vector for filoviruses; recombinant vesicular...vesicular stomatitis virus-based filovirus vaccines. Vaccines discussed are recombinant vesicular stomatitis virus based <b>Ebola</b> virus vaccine, recombinant vesicular stomatitis virus deltaG Marburg virus-Musoke glycoprotein vaccine, and recombinant...', u'PublicationName': u'J.Infect.Dis.', u'Location': u'Galveston, TX, USA', u'Authors': {u'Author': [u'Geisbert T W', u'Feldmann H']}, u'Keywords': {u'Keyword': [u'EBOLA-VACCINE/TR EBOLA-VACCINE/AE EBOLA-VACCINE/PH VACCINES/FT EBOLA-VIRUS/FT RECOMBINANT-VIRAL-VECTOR-VACCINE/FT VIRUS/FT TR/FT AE/FT PH/FT INFECTION,VIRUS/TR INFECTION,VIRUS/OC IN-VIVO/FT CASES/FT RHESUS/FT MACAQUE/FT MONKEY/FT REVIEW/FT VACCINE/FT IMMUNIZATION/FT VACCINATION/FT PROPHYLACTIC-VACCINE/FT LAB.ANIMAL/FT', u'MARBURG-VIRUS/FT RECOMBINANT-VIRAL-VECTOR-VACCINE/FT TR/FT AE/FT PH/FT INFECTION,VIRUS/TR INFECTION,VIRUS/OC IN-VIVO/FT CASES/FT RHESUS/FT MACAQUE/FT MONKEY/FT REVIEW/FT VACCINE/FT IMMUNIZATION/FT VACCINATION/FT PROPHYLACTIC-VACCINE/FT LAB.ANIMAL/FT', u'MEASLES-VACCINE/TR TR/FT INFECTION,VIRUS/TR INFECTION,VIRUS/OC IN-VIVO/FT CASES/FT RHESUS/FT MACAQUE/FT MONKEY/FT REVIEW/FT VACCINE/FT IMMUNIZATION/FT VACCINATION/FT PROPHYLACTIC-VACCINE/FT LAB.ANIMAL/FT']}, u'IssueDate': u'2012-04-25T00:00:00Z', u'MethodOfAction': {u'Method': [u'PROPHYLACTIC-VACCINE', u'RECOMBINANT-VIRAL-VECTOR-VACCINE', u'VACCINE', u'VACCINES']}, u'ThematicGroups': {u'ThematicGroup': [u'Therapeutics', u'Adverse Effects', u'Microbiology']}}{u'PublicationType': u'Conference', u'PublicationYear': 1991, u'Title': u'Inhibition of Ebola Virus Replication In-Vitro and in a SCID Mouse Model by S-Adenosylhomocysteine Hydrolase Inhibitors.', u'@id': u'199125162', u'PreferredNames': {u'PreferredName': [u'3-DEAZAADENOSINE', u'3-DEAZANEPLANOCIN']}, u'Teaser': u'In-vitro, antiviral activity of S-adenosylhomocysteine hydrolase inhibitors against <b>Ebola</b> hemorrhagic fever virus was assessed in Vero E-6 or FRL-103 cells by monoclonal ELISA...only the immune-deficient SCID mouse produced a lethal infection. Infection with <b>Ebola</b> virus (Mayinga strain) produced a uniformly lethal infection, but no hemorrhagic...studies with carbocyclic 3-deazaadenosine and 3-deazaneplanocin A, potent inhibitors of <b>Ebola</b> in-vitro, resulted in increased mean time to death and delay in virus replication...', u'Profiles': {u'Profile': u'Virucides'}, u'MethodOfAction': {u'Method': [u'ADENOSYLHOMOCYSTEINASE-INHIBITORS', u'APOPTOSIS-INDUCERS', u'CYTOSTATICS', u'IMMUNOSUPPRESSIVES', u'VIRUCIDE', u'VIRUCIDES']}, u'PublicationName': u'Antiviral Res.', u'Location': u'Frederick, Md., USA', u'Authors': {u'Author': [u'Huggins J W', u'Zhang Z X', u'Monath T P']}, u'Keywords': {u'Keyword': [u'DEAZANEPLANOCIN-3/PH CYTOSTATICS/FT VIRUCIDES/FT 102052-95-9/FT PH/FT HEM.FEVER/OC INFECTION,VIRUS/OC IMMUNODEFICIENCY-DISEASE/OC IN-VITRO/FT IN-VIVO/FT VERO-CELL/FT FRL103-CELL/FT EBOLA-VIRUS/FT VIRUCIDE/FT MOUSE/FT ANIMAL-MODEL/FT HEART/FT LUNG/FT LIVER/FT SPLEEN/FT KIDNEY/FT BRAIN/FT PROPHYLAXIS/FT TISSUE-CULTURE/FT KIDNEY/FT VIRUS/FT LAB.ANIMAL/FT', u'DEAZAADENOSINE-3/PH IMMUNOSUPPRESSIVES/FT 6736-58-9/FT PH/FT HEM.FEVER/OC INFECTION,VIRUS/OC IMMUNODEFICIENCY-DISEASE/OC IN-VITRO/FT IN-VIVO/FT VERO-CELL/FT FRL103-CELL/FT EBOLA-VIRUS/FT VIRUCIDE/FT MOUSE/FT ANIMAL-MODEL/FT HEART/FT LUNG/FT LIVER/FT SPLEEN/FT KIDNEY/FT BRAIN/FT PROPHYLAXIS/FT TISSUE-CULTURE/FT KIDNEY/FT VIRUS/FT LAB.ANIMAL/FT']}, u'IssueDate': u'1991-01-01T00:00:00Z', u'Settings': {u'Setting': u'Preclinical'}, u'ThematicGroups': {u'ThematicGroup': u'Microbiology'}}{u'PublicationType': u'Journal', u'PublicationYear': 1999, u'Title': u'Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.', u'@id': u'199915695', u'Settings': {u'Setting': u'Clinical'}, u'Profiles': {u'Profile': [u'Immunological', u'Adverse Reactions', u'Infection']}, u'Teaser': u'Anti-<b>Ebola</b> virus immunoglobulins obtained from goats were used to treat 4 subjects suspected of being infected with the <b>Ebola</b> virus. In 3 cases, the i.m. immunoglobulin injections were combined with injections of recombinant alpha-2-interferon. The case of 1 subject is described in detail. This subject had a suspected case of accidental <b>Ebola</b> virus infection and was given anti-<b>Ebola</b> virus goat immunoglobulin. He completely recovered, but it was unclear whether...', u'PublicationName': u'J.Infect.Dis.', u'Location': u'Koltsovo, Russia', u'Authors': {u'Author': [u'Kudoyarova Zubavichene N M', u'Sergeyev N N', u'Chepurov A A', u'Netesov S V']}, u'Keywords': {u'Keyword': u'INFECTION,VIRUS/TR INTERFERON-ALPHA-2/RC IN-VIVO/FT CASE-HISTORY/FT I.M./FT EBOLA-VIRUS/FT SEROTHERAPY/FT ANTIBODY/FT CASES/FT INJECTION/FT VIRUS/FT TR/FT AE/FT'}, u'IssueDate': u'1999-04-23T00:00:00Z', u'ThematicGroups': {u'ThematicGroup': [u'Therapeutics', u'Adverse Effects', u'Microbiology']}}{u'PublicationType': u'Journal', u'PublicationYear': 2007, u'Title': u'Protective efficacy of neutralizing antibodies against Ebola virus infection.', u'@id': u'200718664', u'Settings': {u'Setting': u'Preclinical'}, u'Organisations': {u'Organisation': [u'Univ.Hokkaido', u'CREST', u'Univ.Tokyo', u'Public-Health-Agency-Canada', u'Univ.Wisconsin-Syst.']}, u'Profiles': {u'Profile': [u'Immunological', u'Toxicology', u'Monoclonal Antibodies']}, u'Teaser': u'Although passive transfer of <b>Ebola</b> virus glycoprotein (GP)-specific Ab has been evaluated in mouse and guinea pig models...distinct from those of the Ab tested by others. I.p. treatment with these Ab 2 days after i.p. <b>Ebola</b> virus challenge completely protected most mice. Although i.p. Ab treatment in guinea pigs...as in mice, single-dose treatment of guinea pigs 1 day before, or 1 or 2 days after i.p. <b>Ebola</b> virus challenge did protect some animals. The protective effects seen in these animal models...', u'PublicationName': u'Vaccine', u'Location': u'Sapporo, Hokkaido, Japan', u'Authors': {u'Author': [u'Takada A', u'Ebihara H', u'Jones S', u'Feldmann H', u'Kawaoka Y']}, u'Keywords': {u'Keyword': u'INFECTION,VIRUS/OC WEIGHT-LOSS/AE BODY-WEIGHT/AE MOUSE/FT GUINEA-PIG/FT IN-VIVO/FT I.P./FT IN-VITRO/FT VERO-CELL/FT MONOCLONAL/FT ANTIBODY/FT EBOLA-VIRUS/FT GLYCOPROTEIN/FT MORTALITY/FT SURVIVAL/FT ANTIBODY-RESPONSE/FT ANTIBODY-TITER/FT TOX./FT IMMUNIZATION/FT PASSIVE/FT LAB.ANIMAL/FT INJECTION/FT TISSUE-CULTURE/FT KIDNEY/FT VIRUS/FT IMMUNITY/FT AE/FT PH/FT'}, u'IssueDate': u'2007-05-01T00:00:00Z', u'ThematicGroups': {u'ThematicGroup': [u'Adverse Effects', u'Microbiology']}}{u'PublicationType': u'Journal', u'PublicationYear': 2000, u'Title': u'Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl- L-homocysteine hydrolase inhibitor.', u'IssueDate': u'2000-06-09T00:00:00Z', u'PreferredNames': {u'PreferredName': [u'3-DEAZAARISTEROMYCIN', u'3-DEAZANEPLANOCIN']}, u'Organisations': {u'Organisation': u'U.S.Army-Med.Res.Inst.Infec.Dis.'}, u'Teaser': u'The effect was studied of a single inoculation of carbocyclic 3-deazaadenosine (C-c3Ado; 3-deazaaristeromycin) or 3-deazaneplanocin-A in mice challenged with <b>Ebola</b>-Zaire virus. The drugs protected mice from virus challenge, without causing acute toxicity. Single or multiple doses of the same medications suppressed <b>Ebola</b> replication in severe combined immunodeficient mice (SCID), repeated daily treatment did not eliminate the infection. It is suggested that these compounds may form part of a regimen for the treatment of <b>Ebola</b> virus.', u'Profiles': {u'Profile': u'Virucides'}, u'MethodOfAction': {u'Method': [u'APOPTOSIS-INDUCERS', u'CYTOSTATICS', u'VIRUCIDE', u'VIRUCIDES']}, u'PublicationName': u'Antiviral Res.', u'Location': u'Frederick; Bethesda, Md., USA', u'Authors': {u'Author': [u'Bray M', u'Driscoll J', u'Huggins J W']}, u'Keywords': {u'Keyword': [u'DEAZAARISTEROMYCIN-3/PH VIRUCIDES/FT CYTOSTATICS/FT PH/FT INFECTION,VIRUS/OC EBOLA-VIRUS/FT MOUSE/FT IN-VIVO/FT INJECTION/FT DOSAGE/FT TIME/FT VIRUCIDE/FT DRUG-COMPARISON/FT VIRUS/FT LAB.ANIMAL/FT', u'DEAZANEPLANOCIN-3/PH CYTOSTATICS/FT VIRUCIDES/FT PH/FT INFECTION,VIRUS/OC EBOLA-VIRUS/FT MOUSE/FT IN-VIVO/FT INJECTION/FT DOSAGE/FT TIME/FT VIRUCIDE/FT DRUG-COMPARISON/FT VIRUS/FT LAB.ANIMAL/FT']}, u'@id': u'200021332', u'Settings': {u'Setting': u'Preclinical'}, u'ThematicGroups': {u'ThematicGroup': u'Microbiology'}}